Asset profile
Dabrafenib
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Non-Small Cell Lung Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Dabrafenib: this drug | Approved | Small molecule | BRAF V600E/V600K/V600D (also wild-type BRAF/CRAF) | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK | ||
| Crizotinib | Approved | Small molecule | ALK, ROS1, MET/HGFR, and RON |
…and 45 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(33 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (6)
October 2026 (1)
Phase 2Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2026-10-30 · NCT04675710 · CT.gov ↗
What to watch
November 2026 (2)
Phase 4Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma …Active not recruiting
Est. primary completion 2026-11-05 · NCT03975829 · CT.gov ↗
What to watch
Phase 2Advanced Cancer, Solid Tumor, Haematological MalignancyRecruiting
Est. primary completion 2026-11-25 · NCT05159245 · CT.gov ↗
What to watch
December 2026 (3)
Phase 2Ameloblastoma, BRAF V600E Mutation PositiveRecruiting
Est. primary completion 2026-12-31 · NCT06653517 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 4Advanced Thyroid Cancer Patients Who Received Target TherapyRecruiting
Est. primary completion 2026-12-31 · NCT06195228 · CT.gov ↗
What to watch
2027 (18)
January 2027 (1)
Phase 2Anaplastic Thyroid CancerRecruiting
Est. primary completion 2027-01-01 · NCT06079333 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable MelanomaActive not recruiting
Est. primary completion 2027-03-15 · NCT02196181 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7Active not recruiting
Est. primary completion 2027-04-01 · NCT02231775 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related TumorsActive not recruiting
Est. primary completion 2027-06-20 · NCT04238624 · CT.gov ↗
What to watch
September 2027 (4)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Tumor …Active not recruiting
Est. primary completion 2027-09-02 · NCT04544111 · CT.gov ↗
What to watch
Phase 2CraniopharyngiomaRecruiting
Est. primary completion 2027-09-10 · NCT05525273 · CT.gov ↗
What to watch
Phase 2Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma …Active not recruiting
Est. primary completion 2027-09-30 · NCT03919071 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic CarcinomaRecruiting
Est. primary completion 2027-10-05 · NCT03975231 · CT.gov ↗
What to watch
November 2027 (3)
Phase 2Lung Cancer Stage III, MutationRecruiting
Est. primary completion 2027-11-01 · NCT06563999 · CT.gov ↗
What to watch
Phase 2NeoplasmsActive not recruiting
Est. primary completion 2027-11-10 · NCT06967155 · CT.gov ↗
What to watch
December 2027 (6)
Phase 2BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable), Cetuximab, Dabrafenib, Ipilimumab N01Recruiting
Est. primary completion 2027-12 · NCT07506109 · CT.gov ↗
What to watch
Phase 2Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 …Active not recruiting
Est. primary completion 2027-12-08 · NCT02910700 · CT.gov ↗
What to watch
Phase 1/2Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT01989585 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
Phase 4Thyroid NeoplasmsNot yet recruiting
Est. primary completion 2027-12-31 · NCT07010393 · CT.gov ↗
What to watch
2028 (4)
June 2028 (1)
Phase 2Langerhans Cell Histiocytosis (LCH)Recruiting
Est. primary completion 2028-06-01 · NCT07022834 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1Metastatic Melanoma, BRAF Gene MutationRecruiting
Est. primary completion 2028-07-01 · NCT04903119 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2/3AmeloblastomaNot yet recruiting
Est. primary completion 2028-10-30 · NCT06819605 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2Low Grade Glioma, High Grade GliomaRecruiting
Est. primary completion 2028-12 · NCT06712875 · CT.gov ↗
What to watch
2029 (2)
October 2029 (2)
Phase 2/3Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site …Recruiting
Est. primary completion 2029-10 · NCT07440290 · CT.gov ↗
What to watch
Phase 2/3Haematological Malignancy, Solid TumourRecruiting
Est. primary completion 2029-10 · NCT05722886 · CT.gov ↗
What to watch
2032 (2)
March 2032 (1)
Phase 2BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade GliomaRecruiting
Est. primary completion 2032-03-31 · NCT07110246 · CT.gov ↗
What to watch
December 2032 (1)
Phase 4Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-12-28 · NCT03340506 · CT.gov ↗
What to watch
2033 (1)
November 2033 (1)
Phase 2Rare Malignant NeoplasmRecruiting
Est. primary completion 2033-11-30 · NCT06119789 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.